HUP9904131A3 - Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tomour necrosis factor (tnf) - Google Patents
Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tomour necrosis factor (tnf)Info
- Publication number
- HUP9904131A3 HUP9904131A3 HU9904131A HUP9904131A HUP9904131A3 HU P9904131 A3 HUP9904131 A3 HU P9904131A3 HU 9904131 A HU9904131 A HU 9904131A HU P9904131 A HUP9904131 A HU P9904131A HU P9904131 A3 HUP9904131 A3 HU P9904131A3
- Authority
- HU
- Hungary
- Prior art keywords
- tomour
- mmp
- tnf
- inhibitors
- necrosis factor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9523828.3A GB9523828D0 (en) | 1995-11-22 | 1995-11-22 | Compounds |
| GBGB9607121.2A GB9607121D0 (en) | 1996-04-04 | 1996-04-04 | Compounds |
| PCT/GB1996/002892 WO1997019075A1 (en) | 1995-11-22 | 1996-11-22 | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tumour necrosis factor (tnf) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9904131A2 HUP9904131A2 (hu) | 2000-06-28 |
| HUP9904131A3 true HUP9904131A3 (en) | 2002-04-29 |
Family
ID=26308152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9904131A HUP9904131A3 (en) | 1995-11-22 | 1996-11-22 | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (mmp) and/or tomour necrosis factor (tnf) |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6048841A (enExample) |
| EP (1) | EP0874842B1 (enExample) |
| JP (1) | JP2000500482A (enExample) |
| KR (1) | KR19990067687A (enExample) |
| CN (1) | CN1072667C (enExample) |
| AT (1) | ATE215946T1 (enExample) |
| AU (1) | AU711907B2 (enExample) |
| BR (1) | BR9611636A (enExample) |
| CA (1) | CA2229438C (enExample) |
| CZ (1) | CZ291337B6 (enExample) |
| DE (1) | DE69620639T2 (enExample) |
| ES (1) | ES2172690T3 (enExample) |
| HU (1) | HUP9904131A3 (enExample) |
| IL (1) | IL123431A (enExample) |
| MX (1) | MX9804052A (enExample) |
| NO (1) | NO982290D0 (enExample) |
| NZ (1) | NZ322565A (enExample) |
| PL (1) | PL326710A1 (enExample) |
| WO (1) | WO1997019075A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6673927B2 (en) | 1996-02-16 | 2004-01-06 | Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. | Farnesyl transferase inhibitors |
| US6953788B1 (en) | 1996-09-19 | 2005-10-11 | Aventis Pharmaceuticals Inc. | 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase |
| RU2201931C2 (ru) | 1996-11-20 | 2003-04-10 | Биомежер Инкорпорэйтед | Ингибиторы фарнезилтрансферазы и способы ингибирования фарнезилтрансферазы |
| MXPA02010993A (es) * | 2000-05-12 | 2003-03-10 | Genzyme Corp | Reguladores de transmision de la tnf-alfa. |
| WO2001087870A1 (en) | 2000-05-15 | 2001-11-22 | Darwin Discovery Limited | Hydroxamic acid derivatives |
| SE0100903D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0100902D0 (sv) * | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| SE0103710D0 (sv) * | 2001-11-07 | 2001-11-07 | Astrazeneca Ab | Compounds |
| EP1474425B9 (en) * | 2002-01-07 | 2008-07-02 | Eisai Co., Ltd. | Deazapurines and uses thereof |
| SE0202539D0 (sv) * | 2002-08-27 | 2002-08-27 | Astrazeneca Ab | Compounds |
| GB0221246D0 (en) * | 2002-09-13 | 2002-10-23 | Astrazeneca Ab | Compounds |
| PT1562571E (pt) * | 2002-11-21 | 2011-11-25 | Genzyme Corp | Combinação de derivados de diamina e agentes imunossupressores para a indução da tolerância imunológica |
| AU2003291134A1 (en) * | 2002-11-21 | 2004-06-18 | Genzyme Corporation | Use of diamide derivatives for inhibiting chronic tissue transplant rejection |
| US20040259744A1 (en) * | 2003-12-19 | 2004-12-23 | Meidong Yang | Skin and hair cleansers containing sulfur |
| US7648992B2 (en) | 2004-07-05 | 2010-01-19 | Astrazeneca Ab | Hydantoin derivatives for the treatment of obstructive airway diseases |
| SE0401762D0 (sv) * | 2004-07-05 | 2004-07-05 | Astrazeneca Ab | Novel compounds |
| SE0403085D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Novel componds |
| SE0403086D0 (sv) * | 2004-12-17 | 2004-12-17 | Astrazeneca Ab | Compounds |
| TW200831488A (en) * | 2006-11-29 | 2008-08-01 | Astrazeneca Ab | Novel compounds |
| PL227790B1 (pl) | 2015-08-13 | 2018-01-31 | Slaski Univ Medyczny W Katowicach | Fosfoniany acetylenowych pochodnych betuliny o działaniu przeciwnowotworowym, sposób ich wytwarzania i zastosowanie. |
| CN120617250A (zh) * | 2025-07-04 | 2025-09-12 | 南京农业大学 | 小分子化合物Nec-1s在制备治疗脑膜炎药物中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3348725B2 (ja) * | 1992-04-07 | 2002-11-20 | ブリティッシュ バイオテック ファーマシューティカルズ リミテッド | ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤 |
| GB9215665D0 (en) * | 1992-07-23 | 1992-09-09 | British Bio Technology | Compounds |
| GB9323165D0 (en) * | 1993-11-10 | 1994-01-05 | Chiros Ltd | Compounds |
| GB9404046D0 (en) * | 1994-03-03 | 1994-04-20 | Smithkline Beecham Corp | Novel compounds |
| ES2133807T3 (es) * | 1994-10-05 | 1999-09-16 | Darwin Discovery Ltd | Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteasas. |
-
1996
- 1996-11-22 CA CA002229438A patent/CA2229438C/en not_active Expired - Fee Related
- 1996-11-22 DE DE69620639T patent/DE69620639T2/de not_active Expired - Fee Related
- 1996-11-22 JP JP9519522A patent/JP2000500482A/ja not_active Ceased
- 1996-11-22 CZ CZ19981455A patent/CZ291337B6/cs not_active IP Right Cessation
- 1996-11-22 NZ NZ322565A patent/NZ322565A/xx unknown
- 1996-11-22 BR BR9611636-6A patent/BR9611636A/pt unknown
- 1996-11-22 IL IL12343196A patent/IL123431A/en not_active IP Right Cessation
- 1996-11-22 PL PL96326710A patent/PL326710A1/xx unknown
- 1996-11-22 US US08/755,071 patent/US6048841A/en not_active Expired - Fee Related
- 1996-11-22 EP EP96939208A patent/EP0874842B1/en not_active Expired - Lifetime
- 1996-11-22 HU HU9904131A patent/HUP9904131A3/hu unknown
- 1996-11-22 AT AT96939208T patent/ATE215946T1/de not_active IP Right Cessation
- 1996-11-22 AU AU76343/96A patent/AU711907B2/en not_active Ceased
- 1996-11-22 KR KR1019980703717A patent/KR19990067687A/ko not_active Ceased
- 1996-11-22 WO PCT/GB1996/002892 patent/WO1997019075A1/en not_active Ceased
- 1996-11-22 ES ES96939208T patent/ES2172690T3/es not_active Expired - Lifetime
- 1996-11-22 CN CN96198507A patent/CN1072667C/zh not_active Expired - Fee Related
-
1998
- 1998-05-20 NO NO982290A patent/NO982290D0/no not_active Application Discontinuation
- 1998-05-21 MX MX9804052A patent/MX9804052A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CZ145598A3 (cs) | 1998-08-12 |
| ATE215946T1 (de) | 2002-04-15 |
| WO1997019075A1 (en) | 1997-05-29 |
| AU7634396A (en) | 1997-06-11 |
| HUP9904131A2 (hu) | 2000-06-28 |
| IL123431A (en) | 2001-05-20 |
| EP0874842B1 (en) | 2002-04-10 |
| AU711907B2 (en) | 1999-10-21 |
| NO982290L (no) | 1998-05-20 |
| ES2172690T3 (es) | 2002-10-01 |
| NZ322565A (en) | 1999-11-29 |
| CN1202895A (zh) | 1998-12-23 |
| IL123431A0 (en) | 1998-09-24 |
| PL326710A1 (en) | 1998-10-26 |
| JP2000500482A (ja) | 2000-01-18 |
| CA2229438A1 (en) | 1997-05-29 |
| US6048841A (en) | 2000-04-11 |
| MX9804052A (es) | 1998-09-30 |
| CA2229438C (en) | 2006-01-17 |
| CN1072667C (zh) | 2001-10-10 |
| DE69620639T2 (de) | 2002-10-17 |
| NO982290D0 (no) | 1998-05-20 |
| DE69620639D1 (de) | 2002-05-16 |
| BR9611636A (pt) | 1999-12-28 |
| EP0874842A1 (en) | 1998-11-04 |
| CZ291337B6 (cs) | 2003-02-12 |
| KR19990067687A (ko) | 1999-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4267293A (en) | Use of MMP inhibitors | |
| IL123431A0 (en) | Mercaptoalkylpeptidyl compounds having an imidazole substituent and their use as inhibitors of matrix metalloproteinases (MMP) and/or tumour necrosis factor (TNF) | |
| PL330974A1 (en) | Substituted derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and of tumor necrosis factor (tnf) | |
| FI973974A7 (fi) | Aryylisulfonyylihydroksaamihappojohdannaisia MMP- ja TNF-inhibiittorei na | |
| AU1116497A (en) | Inhibitors of cyclin-dependent kinases | |
| PL319503A1 (en) | Peptide compounds and their therapeutic application as inhibitors | |
| AU4915796A (en) | Inhibitors of prenyl transferases | |
| PL332187A1 (en) | Substitution derivatives of indazole and their application as inhibitors of phosphodiesterase (pde) of iv type and tumor necrosis factor (tnf) | |
| PL329836A1 (en) | Substituted indazole derivatives and their application as inhibitors of phosphosiesterase (pde) type iv and of tumor necrosis factor (tnf) formation | |
| PL327185A1 (en) | Thyrosine derivatives as inhibitors of integrin-alpha v | |
| AU5918494A (en) | Heterocyclic inhibitors of farnesyl protein transferase | |
| AU8760798A (en) | Irreversible inhibitors of tyrosine kinases | |
| AU5665396A (en) | Novel hydroxamic acid and amino-carboxylate compounds as met alloprotease and tnf inhibitors | |
| AU5453994A (en) | Inhibitors of farnesyl-protein transferase | |
| PL331254A1 (en) | Phosphonianic inhibitors of matrix metaloproteases | |
| PL327569A1 (en) | Promedications of thrombosin inhibitors | |
| AU1988495A (en) | Inhibitors of farnesyl-protein transferase | |
| AU6157396A (en) | Bis-arylsulfonylaminobenzamide derivatives and the use there of as factor xa inhibitors | |
| AU3373195A (en) | Inhibitors of farnesyl-protein transferase | |
| PL331047A1 (en) | Novel amidinic derivatives and their application as inhibitors of thrombosin | |
| AU9663798A (en) | Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | |
| AU1417092A (en) | 1-imidazolgemethyl benzofuran derivatives as inhibitors of angiotensin ii activity | |
| PL333112A1 (en) | Substitute derivatives of 4-biphenyl-4-hydroxybutyric acid as inhibitors of matrix metaloproteases | |
| AU2159495A (en) | Methods and compositions for inhibition of hepatic clearance of tissue factor pathway inhibitor | |
| AU1783092A (en) | Inhibitors of protein kinase c function |